The Translational Cancer Discovery Group is particularly interested in engineering novel antibody-based cancer therapies that can directly target certain tumour cells and, simultaneously, also targets key immune cell proteins, therefore combining two cancer therapy approaches in one drug. . We are validating these drug candidates using genetically-engineered mouse models of cancer along with state-of-the art flow cytometry, transcriptomics analysis and other tissue imaging platforms.
Importantly, our approach to cancer drug development is informed by the “reverse translational research” paradigm. This means that we utilise cutting-edge translational experiments using patient-derived materials from on-going cancer clinical trials to help understand mechanisms and design the next generation of cancer therapies. Currently, we are engaged in clinical trial activities that include experimental treatments for patients with non-small cell lung cancer, head and neck squamous cell carcinoma, colorectal cancer and breast cancer.
We gratefully acknowledge the support of the following funding agencies